Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
73.1K
-
Shares change
-
+38K
-
Total reported value, excl. options
-
$4.41M
-
Value change
-
+$2.29M
-
Number of buys
-
1
-
Price
-
$60.39
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q4 2023
1 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q4 2023.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.1K shares
of 63.5M outstanding shares and own 0.12% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (8.49M shares), FMR LLC (3.85M shares), Avoro Capital Advisors LLC (2.58M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.31M shares), CITADEL ADVISORS LLC (2.01M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.53M shares), T. Rowe Price Investment Management, Inc. (1.22M shares), FEDERATED HERMES, INC. (1.06M shares), and Darwin Global Management, Ltd. (1.04M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.